Comparison of high and low dose cyclophosphamide therapy in rheumatoid arthritis

Abstract

Eighty-eight patients with active rheumatoid arthritis from 8 Cooperating Clinics were evaluated in a 32-week controlled, double-blind trial comparing 150 mg daily to 75 mg cyclophosphamide daily. Improvement in the arthritis was seen in both groups, and there were no important differences between the two treatment groups in any of the 8 variables used to measure disease activity. Untoward effects were also similar for the two groups. These results differ from preliminary results reported earlier.